Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

Survival for older patients with acute myeloid leukemia (AML) unsuitable for intensive chemotherapy is unsatisfactory. Standard nonintensive therapies have low response rates and only extend life by a few months. Quizartinib is an oral Fms-like tyrosine kinase 3 (FLT3) inhibitor with reported activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dennis, Mike, Thomas, Ian F., Ariti, Cono, Upton, Laura, Burnett, Alan K., Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven, Clark, Richard E., Copland, Mhairi, Russell, Nigel, Hills, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714727/
https://www.ncbi.nlm.nih.gov/pubmed/34597366
http://dx.doi.org/10.1182/bloodadvances.2021005038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714727/
https://www.ncbi.nlm.nih.gov/pubmed/34597366
http://dx.doi.org/10.1182/bloodadvances.2021005038

Ejemplares similares